Definium Therapeutics, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $117.7M | $65.3M | $52.1M | $36.2M | $34.8M | $18.6M | — |
| SG&A Expense | — | $48.6M | $38.6M | $41.7M | $30.2M | $59.1M | $14.4M | — |
| Operating Income | — | $-166.3M | $-103.9M | $-93.9M | $-66.3M | $-93.9M | $-33.0M | $-10.7M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | $5.5M | $2.3M | $920.0K | — | — | — | — |
| Pretax Income | — | $-183.8M | $-108.7M | $-95.7M | $-56.8M | $-94.2M | $-33.9M | $-10.7M |
| Income Tax Expense | — | $0 | — | — | — | $-1.2M | — | — |
| Net Income | — | $-183.8M | $-108.7M | $-95.7M | $-56.8M | $-93.0M | $-33.9M | — |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | $-0.13 | — |
| EPS (Diluted) | — | $-2.06 | $-1.54 | $-2.44 | $-1.84 | $-3.40 | $-0.13 | — |
| Shares Outstanding (Basic) | 99.7M | 89.3M | 70.5M | 39.2M | 30.9M | 27.4M | — | — |
| Shares Outstanding (Diluted) | 99.7M | 89.3M | 70.5M | 39.2M | 30.9M | 27.4M | — | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |